TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A study of prospectively logged menstrual cycles found that users of combined GLP-1/GIP receptor agonists had a larger average reduction in cycle length and lower cycle variability than GLP-1-only users and non-users. The observational findings, presented at the American Society for Reproductive Medicine meeting, do not show that the drugs caused the changes.
Women reporting use of a combined GLP-1/GIP receptor agonist had a larger average reduction in menstrual cycle length and less cycle variability than women using GLP-1 drugs alone or taking neither type, according to an analysis presented at the American Society for Reproductive Medicine’s annual meeting. The prospective cohort findings show an association, not proof that the medication caused the changes.
The analysis by Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health and colleagues included 1,945 participants and 70,134 logged cycles. Of those participants, 123 reported using a combined GLP-1/GIP drug in the past year, 258 reported GLP-1 medication use, and 1,564 were never-users. Participants shared menstrual records logged through Apple HealthKit and answered surveys about medication use, demographics and medical history.
Compared with baseline, mean cycle length fell by 2.5 days among combined-drug users, versus 0.4 days for GLP-1-only users and 0.8 days for never-users. Mean individual cycle variability was 6.93 days among combined-drug users, compared with 7.45 days for GLP-1 users and 7.46 days for never-users. The researchers also reported larger differences in a subgroup identified as having polyendocrine metabolic ovarian syndrome (PMOS), a term the report says was formerly called polycystic ovary syndrome (PCOS).
The study was not a randomized trial, and the groups differed in some characteristics: medication users were older on average and had higher rates of PMOS, infertility, type 2 diabetes and hypertension than never-users. The most commonly reported reason for medication use was weight loss for health, followed by weight loss for appearance and PMOS. The researchers did not use sensor-based data in the analysis.
What Cycle Changes Could Mean
Menstrual regularity can matter beyond pregnancy planning. Rachel Weinerman, an ob/gyn and reproductive endocrinologist at Case Western Reserve University who was not involved in the research, told MedPage Today that irregular periods may also signal underlying health issues. She said the results are a reminder that people with PMOS may respond differently from other patients with similar characteristics.
The findings may help researchers examine whether incretin medicines are associated with reproductive changes as well as metabolic ones. But they do not establish a reason to prescribe these drugs to improve menstrual regularity. The reported data cannot determine whether cycle changes reflect medication effects, weight loss, other health changes, or differences among the participants.
The distinction matters because a medication’s association with more regular cycles is not evidence that it improves ovulation, fertility, or other reproductive outcomes. The analysis measured cycle length and variability; it did not establish those broader outcomes.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Hyperice Hypervolt Go 3 Portable Percussion Massage Gun with Carry Case
As an affiliate, we earn on qualifying purchases.
How Researchers Tracked Cycles
The Apple Women’s Health Study is a longitudinal digital cohort of about 147,000 U.S. women. For this analysis, researchers included participants younger than 50 who had logged at least three cycles, had cycle lengths from 10 to 90 days, and were not pregnant, lactating or using hormones. The analysis focused on medication use reported for the previous year and on prospectively logged menstrual cycles.
Earlier retrospective studies had suggested a possible link between GLP-1 medicines and menstrual regularity, but the researchers said prospective studies had not examined the issue as a primary endpoint. Mahalingaiah told MedPage Today the team wanted to examine the potential impact with more detail. More than 10 million women in the United States use a GLP-1 or combined GLP-1/GIP medicine, according to the report. Tirzepatide, sold as Zepbound, was identified as the only FDA-approved GLP-1/GIP drug.
“This more pronounced reduction among PMOS individuals might suggest a separate pathway that might focus on ovulatory health in addition to those metabolic parameters that support ovulation, but further research is necessary.”
— Shruthi Mahalingaiah, MD, MS, of the Harvard T.H. Chan School of Public Health
Cause and Outcomes Remain Unclear
Because this was an observational analysis, it cannot show that the medicines caused the differences in cycle length or variability. Weight change, underlying conditions and other differences between users and non-users could have contributed. The report also does not establish whether the changes persisted, whether they reflect more frequent ovulation, or whether they affect fertility or other health outcomes.
The findings combine medication categories and do not provide a breakdown by specific drug. The researchers said future manuscripts will examine results by individual agents. The reported analysis also does not establish how broadly the results apply beyond participants who met its eligibility criteria and logged cycles using the study’s digital platform.
Further Drug-Specific Research
Mahalingaiah said future reports will break down the findings by particular medicines. Further research will be needed to test whether the observed associations hold in other populations and to clarify the roles of weight change and metabolic health. Studies designed to assess ovulation and other reproductive outcomes would be needed before drawing conclusions about those effects.
For now, the meeting presentation adds prospective cycle-tracking data to a developing area of research, but it does not change what the results can establish: combined-drug use was associated with measured cycle changes in this cohort, while cause and clinical implications remain unsettled.
Key Questions
What did the study find?
Users of combined GLP-1/GIP receptor agonists had a larger average reduction in cycle length and lower cycle variability than GLP-1-only users and never-users. The study found an association, not proof of a drug effect.
Does this prove incretin drugs make periods more regular?
No. The analysis was observational, so it cannot establish that the medicines caused the differences. Other factors, including weight change and underlying health conditions, may have played a role.
What was the PMOS subgroup finding?
Among participants identified as having PMOS, mean cycle variability was 5.80 days for combined-drug users, 7.34 days for GLP-1 users and 9.45 days for never-users. The report notes that PMOS was formerly called PCOS.
Did the study measure fertility or ovulation?
The reported analysis measured cycle length and variability. It did not establish effects on fertility or confirm that participants ovulated more often.
What research is expected next?
Mahalingaiah said future manuscripts will report findings by specific medication. Further studies are needed to examine causes and reproductive outcomes.
Source: medpagetoday.com
